Protalix BioTherapeutics, Inc. — Director's Dealing 2020

Feb 5, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Protalix BioTherapeutics, Inc. (PLX)
CIK: 0001006281
Period of Report: 2020-02-03

Reporting Person: Bronfeld Zeev (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-02-03	Stock Options (Right to Buy)	$3.70	A	240000	Acquired	2030-02-03	Common Stock (240000)	Direct

Footnotes

F1: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended.